Asimov
PrivateLast Round
Series B
Jan 5, 2023
Total Funding Raised
$211.56M
Company Overview
Asimov operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2023.
Asimov is a biotechnology company that provides mammalian cell engineering software and synthetic biology platforms to accelerate the design and production of biologics and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asimov Comparables
Compare Asimov with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 64x Bio | 84% | |
| ATUM | 79% | |
| Dyno Therapeutics | 77% |
For institutional investors. Book with your work email.
Asimov Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2023 | ||||
| Series A | Dec 31, 2019 | ||||
| Follow-on Offering | May 22, 2019 | ||||
| Seed | Dec 19, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Asimov Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Seed |
| CPP Investments | Series B |
| Horizons Ventures | Series B, Series A |
| Fidelity Management & Research Company | Series B |
| Lux Capital | Series B |
| Koch Disruptive Technologies | Series B |
| Pillar VC | Seed, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
Launched the RNA Edge System, an AI and synthetic biology platform.
- Mar 17, 2026
Partnered with Score Pharma, Inc. for antibody therapeutics.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 21, 2026
Under the licensing agreement announced in Massachusetts on Oct 21st '26, LG Chem Ltd will in-license Asimov, Inc.'s CHO Edge System to support biologics cell line development.
- signs_new_clientOct 21, 2026
Asimov, Inc. signs LG Chem Ltd as a new client through a licensing agreement for the CHO Edge System, which supports biologics cell line development activities, in Massachusetts on Oct 21st '26.
- receives_financingOct 12, 2026
As of Oct '26, Asimov, Inc. reports $234M raised across 8 funding rounds, including 4 Seed and 4 Early-Stage rounds.
- is_developingOct 3, 2026
Asimov, Inc. is building an AI-native synthetic biology platform to advance therapeutic development, as announced on Oct 2nd '26.
- is_developingOct 3, 2026
On Oct 2nd '26, Asimov, Inc. announced a strategic collaboration with Lonza to advance In Vivo lentiviral vector manufacturing by combining Asimov's LV Edge system cell line technologies with Lonza's process development, scale-up, analytics and GMP manufacturing expertise.
For institutional investors. Book with your work email.
Asimov Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Asimov's valuation, stock price, and market status.
Is Asimov a public or private company?
Asimov is a private company.
What is the current stock price of Asimov?
Asimov is a private company, so its shares have no public market price. Caplight tracks Asimov's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Asimov worth (valuation)?
Valuation information for Asimov is not publicly available.
Can I buy Asimov stock?
Asimov shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Asimov's last funding round?
Asimov's most recent funding round was Series B on January 5, 2023.
Who are the main investors in Asimov?
Key investors in Asimov include Andreessen Horowitz, CPP Investments, Horizons Ventures.
Will Asimov IPO soon?
No public IPO plans have been announced for Asimov.
How can I track Asimov secondary market activity?
Caplight tracks bids, offers, and trades in Asimov's shares on secondary markets.